Immunologic Research

, Volume 65, Issue 1, pp 363–368 | Cite as

A novel bedside test for ACPA: the CCPoint test is moving the laboratory to the rheumatologist’s office

  • Gisele Zandman Goddard
  • Alessandra Soriano
  • Boris Gilburd
  • Merav Lidar
  • Shaye Kivity
  • Ron Kopilov
  • Pnina Langevitz
  • Yehuda Shoenfeld
  • Nancy Agmon-Levin
Mechanism in Autoimmunity


Rheumatoid Arthritis (RA) is an autoimmune destructive joint disease affecting 1 % of the general population. In recent years, the benefits of identifying RA at an early stage and initiating therapy before joint damage occurs have been acknowledged. An elevated anti-citrullinated peptide antibody (ACPA) level serves as a marker for the early diagnosis of RA. Often the diagnosis is delayed because conventional methods of antibody detection require referral to a specific laboratory. In the current study, we determined the diagnostic accuracy of a new lateral flow point-of-care kit available for ACPA detection in the rheumatologist office. The presence of ACPA was determined by the visually read, qualitative rapid CCPoint® test (Euro-Diagnostica, Malmö, Sweden) compared to routinely used ELISA assays (Immunoscan CCPlus®-Euro-Diagnostica, Sweden, and QuantLite® CCP3-INOVA Diagnostics Inc., USA), in the sera of 184 patients: early RA(n = 38), established RA (n = 84), inflammatory arthritis(n = 34) and systemic lupus erythematosus (SLE) (n = 28). ACPA was detected in 18/38(47 %), 53/84(63 %), 2/34(6 %) and 2/28(7 %) of patients with early RA, established RA, inflammatory arthritis and SLE, respectively. The sensitivity and specificity, negative and positive predictive values of the CCPoint® test were equivalent to the Immunoscan CCPlus® and Quanta Lite® CCP3 ELISA assays. Correlation between ACPA positive results detected in the different assays was 97 %, while negative agreement reached 98 %. Excellent correlation (100 %) was observed between CCPoint® results obtained using capillary blood versus serum. CCPoint® is a novel technology that allows for a rapid accurate analysis of ACPA and diagnosis during the patient’s visit in the rheumatologist office.


ACPA POC CCPoint test Rheumatoid arthritis Diagnostics 


  1. 1.
    Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4:130–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20:849–63.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71:1921–3.CrossRefPubMedGoogle Scholar
  4. 4.
    van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(861–870):5.Google Scholar
  5. 5.
    White D, Pahau H, Duggan E, Paul S, Thomas R. Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ Open. 2013;3(7):e003083. doi: 10.1136/bmjopen-2013-003083.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Suwannalai P, Britsemmer K, Knevel R, Scherer H, Levarht EW, van der Helm-van Mil AH, van Schaardenbutg D, Huizinga TW, Toes RE, Trouw LA. Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2014;73:270–6.CrossRefPubMedGoogle Scholar
  7. 7.
    De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P, on behalf of the CareRA study group. A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. Scand J Rheumatol. 2014;43:627–31.Google Scholar
  8. 8.
    Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, on behalf of the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) investigators, et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev. 2012;11:815–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factors tests for rheumatoid arthritis. Autoimmune Dis. 2012;2012:734069.PubMedCentralGoogle Scholar
  10. 10.
    Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, for the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group), et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther. 2013;15:R16.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    van der Liden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH, Comparison of the 1987 American College of Rheumatology Criteria and the 2010. American college of rheumatology/European league against rheumatism criteria. Arthritis Rheum. 2011;63:37–42.CrossRefGoogle Scholar
  12. 12.
    Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;147:797–808.CrossRefGoogle Scholar
  13. 13.
    Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem. 2007;53:1527–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70:392–9.PubMedGoogle Scholar
  15. 15.
    Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, et al. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol. 2011;29:500–5.PubMedGoogle Scholar
  16. 16.
    Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz DR, Sanchez- Ramon S, Rodriguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–24.CrossRefPubMedGoogle Scholar
  17. 17.
    van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Liao J, Ip WS, Cheung KY, Wan WM, Cautherley GW, Cai X, et al. Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis. Clin Chim Acta. 2011;412:778–81.CrossRefPubMedGoogle Scholar
  19. 19.
    Egerer K, Feist E, Burmester GR. The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtsch Arztebl Int. 2009;106:159–63.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Snijders GF, Broeder AA, Bevers K, Jeurissen ME, van Eerd JE, van den Hoogen FH. Measurement characteristics of a new rapid antiCCP2 test compared to the anti-CCP2 ELISA. Scand J Rheuamtol. 2008;37:151–4.CrossRefGoogle Scholar
  22. 22.
    Renger F, Bang H, Feist E, Fredenhagen G, Natusch A, Backhaus M, et al. Immediate determination of ACPA and rheumatoid factor—a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay. Arthritis Res Ther. 2010;12:R120.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rojanasantikul P, Pattrapornpisut P, Anuruckparadorn K, Katchamart W. The performance of a point of care for detection anf anti-mutated citrullinated vimentin and rheumatoid factor in early rheumatoid arthritis. Clin Rheumatol. 2014;33:919–23.CrossRefPubMedGoogle Scholar
  24. 24.
    Szekanecz Z, Szabo Z, Zeher M, Soos L, Danko K, Horvath I, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res. 2013;56:439–43.CrossRefPubMedGoogle Scholar
  25. 25.
    Nicaise-Roland P, Noguiera L, Demattei C, de Chaisemartin L, Rincheval N, Cornillet M, et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis. 2013;72:357–62.CrossRefPubMedGoogle Scholar
  26. 26.
    Matsson P. Is there a future for multiplexed technologies in the point-of care setting? Bioanalysis. 2011;3:2049–52.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Gisele Zandman Goddard
    • 1
    • 2
    • 5
  • Alessandra Soriano
    • 1
    • 4
  • Boris Gilburd
    • 1
  • Merav Lidar
    • 2
    • 3
  • Shaye Kivity
    • 2
    • 3
  • Ron Kopilov
    • 1
  • Pnina Langevitz
    • 2
    • 3
  • Yehuda Shoenfeld
    • 1
    • 6
  • Nancy Agmon-Levin
    • 1
    • 2
  1. 1.Zabludowicz Center for Autoimmune DiseasesChaim Sheba Medical CenterTel-HashomerIsrael
  2. 2.Sackler School of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.The Zabludowicz Center for Autoimmune Diseases, Rheumatology UnitSheba Medical CenterTel-HashomerIsrael
  4. 4.Department of Clinical Medicine and RheumatologyCampus Bio-Medico UniversityRomeItaly
  5. 5.Department of Medicine C Wolfson Medical CenterHolonIsrael
  6. 6.Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of MedicineTel-Aviv UniversityTel-AvivIsrael

Personalised recommendations